HC Wainwright & Co. Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $65

Benzinga Newsdesk www.benzinga.com Positive 80.6%

Neg 0% Neu 0% Pos 80.6%

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Eton Pharmaceuticals (NASDAQ:ETON) with a Buy and raises the price target from $57 to $65.